Recruiting

Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

ClinicalTrials.gov IDNCT07179809
PhaseNA
Enrollment100
SponsorM.D. Anderson Cancer Center
Age18 Years
SexFEMALE
I'm interested View official listing

Conditions studied

Metastatic Breast Cancer

About this study

The research study is to learn how the ACLP can best support patients with stable HR+/HER2- MBC.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: 1. Patients with HR+/HER2 negative MBC 2. On first- or second-line treatment 3. Life expectancy at least 12 months 4. Only females 5. Age 18 years or older 6. Able to read, write, and speak English 7. Willingness to follow protocol requirements 8. Have a smartphone with access to cellular service or computer access with internet service 9. Oriented to person, place, and time 10. Consume less than 3 servings of fruit and vegetable/day 11. Engage in less than 150 minutes moderate/vigorous intensity activity per week, defined as anything that causes small increases in breathing or heart rate for a sustained amount of time (e.g., brisk walking, bicycling) 12. Engage in a mind-body practice less than 4 times a month Exclusion Criteria: 1. Another primary cancer diagnosis within past 5 years (not including non-melanoma skin cancers) 2. Any major thought disorder (e.g., schizophrenia, dementia) 3. Communication barriers (e.g., hard of hearing) 4. Poorly-controlled or uncontrolled diabetes in the opinion of the physician(s) 5. Extreme mobility issues (e.g., unable to get in and out of a chair unassisted)

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.